enGene Therapeutics Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
ENGN Nasdaq 2830 www.engene.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for enGene Therapeutics Inc.

enGene Reports Third Quarter 2026 Financial Results and Provides Business Update - Sep 8th, 2026 5:30 am
enGene to Participate in Upcoming Investor Conferences - Sep 1st, 2026 6:30 am
enGene Eyes 2027 Approval as Detalimogene Targets Expanding Bladder Cancer Market - Aug 13th, 2026 9:07 am
enGene to Host Virtual KOL Event to Discuss Emerging Non-Muscle Invasive Bladder Cancer (NMIBC) Market Insights, on August 11, 2026 - Aug 4th, 2026 6:00 am
enGene Focuses Board to Support Planned Upcoming Regulatory and Commercial Milestones - Jul 16th, 2026 6:00 am
Rectify Pharmaceuticals Announces Appointment of Constantine Chinoporos as Executive Chairman - Jul 15th, 2026 7:00 am
Neumora depression drug fails; EnGene to cut 50% of staff - Jun 16th, 2026 3:08 am
enGene Reports Second Quarter 2026 Financial Results and Provides Business Update - Jun 15th, 2026 7:00 am
A Look At enGene Therapeutics (ENGN) Valuation After LEGEND Trial Update And Legal Investigations - May 10th, 2026 7:11 pm
enGene Bladder Cancer Data Shows Promise, but Durability Questions Remain - May 8th, 2026 5:05 pm
enGene Therapeutics (ENGN) Is Down 76.3% After Mixed LEGEND Phase 2 Durability Data Release Has The Bull Case Changed? - May 8th, 2026 3:27 pm
enGene Therapeutics hit by analyst downgrades as drug data disappoints - May 8th, 2026 9:41 am
enGene Shares Detalimogene NMIBC Trial Changes, FDA Endpoint Shift, and 2027 Approval Path at Conference - Mar 15th, 2026 3:33 pm
enGene Highlights 2026 Data Catalysts, BLA Plans for Bladder Cancer Gene Therapy at Barclays Conference - Mar 15th, 2026 2:37 pm
enGene CEO Pitches Detalimogene as Community-Friendly NMIBC Option, Teases Q2 LEGEND Data Update - Mar 15th, 2026 1:03 pm
enGene Maps BLA by End-2026, Targets 2027 Launch for Lead NMIBC Therapy at Oppenheimer Conference - Feb 27th, 2026 5:16 pm
Jefferies Sets a $28 PT for enGene Holdings Inc. (ENGN) - Feb 16th, 2026 5:04 am